In episode 480, James and Mike talk about two recent meta-analyses that have done a solid job of looking at the impact of lowering blood pressure and using SGLT-2s and GLP-1s to reduce risk. Both publications lend credence to the concept of focusing much more on risk reduction goals than blood pressure or glucose thresholds.
1) Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
Lancet. 2021 May 1;397(10285):1625-1636.
2) Decisions about antihypertensive treatment should focus on reducing cardiovascular risk
Lancet. 2021 May 1;397(10285):1598-1599
3) Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573.